Hepatocellular carcinoma stem cells: the current state of small molecule-based inhibitors

Area of Science:

• Hepatology
• Oncology
• Cancer Stem Cell Biology

Background:

• Hepatocellular carcinoma (HCC) is the most common liver cancer, with advanced stages requiring systemic treatment.
• Despite recent therapeutic advances, poor prognosis persists due to drug resistance, relapse, and metastasis.
• Cancer stem cells (CSCs) are implicated in HCC tumorigenesis, metastasis, and treatment resistance.

Purpose of the Study:

• To review emerging small compounds targeting hepatocellular carcinoma cancer stem cells (HCC CSCs).
• To provide insights for future research and drug development against HCC CSCs.

Main Methods:

• Literature review focusing on preclinical and clinical stage drugs targeting HCC CSCs.
• Selection and discussion of small compounds with potential to eradicate HCC CSCs.

Main Results:

• Identification of various HCC CSC markers.
• Reported intracellular signaling pathways and extracellular factors as potential therapeutic targets.
• Emerging small compounds show promise in preclinical and clinical development.

Conclusions:

• Targeting HCC CSCs is a viable strategy to improve treatment outcomes.
• Further research into small compounds can lead to novel therapies for hepatocellular carcinoma.
• Developing targeted drugs to eradicate HCC CSCs holds potential for significantly improving patient survival.